Polyrizon PLRZ
NASDAQ PLRZ
$10.30 -0.19 (-1.81%)
As of: Aug 21, 2026 · 3:34 PM EDT

Polyrizon (PLRZ) Liabilities and Shareholders Equity (2023 - 2025)

Polyrizon's (PLRZ) quarterly Liabilities and Shareholders Equity came in at $21.4 million in Q4 2025, up 286.46% YoY from $5.5 million in Q4 2024, and up 14.4% on a QoQ basis from $18.7 million in Q2 2025.

Polyrizon (PLRZ) Liabilities and Shareholders Equity (2023 - 2025) Analysis & Trends

Polyrizon (PLRZ) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $21.4 million in Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 286.46% year-over-year to $21.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $46.3 million (changed N/A YoY) and the FY2025 annual result came in at $21.4 million, up 286.46% from the prior year.
  • Liabilities and Shareholders Equity climbed to $21.4 million in Q4 2025, from $18.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $21.4 million in Q4 2025 to a low of $559000.0 in Q4 2023.
  • A 3-year average of $11.6 million and a median of $12.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 892.31% — and 2025, when it soared 286.46%.
  • Tracing PLRZ's Liabilities and Shareholders Equity over 3 years: stood at $559000.0 in 2023, then surged by 892.31% to $5.5 million in 2024, then soared by 286.46% to $21.4 million in 2025.
  • The last three Liabilities and Shareholders Equity figures came in at $21.4 million (Q4 2025), $18.7 million (Q2 2025), and $5.5 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 Polyrizon 7.27 Mn -4.22 Mn - 21.44 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 21.44 Mn
Jun 30, 2025 18.74 Mn
Dec 31, 2024 5.55 Mn
Dec 31, 2023 559,000.00